Russell Investments Group
EIDX

Russell Investments Group’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Russell Investments Group’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-29,544
Closed -$3.88M – 3266
2020
Q4 		$3.88M Sell
29,544
-1,908
-6% -$169K 0.01% 1386
2020
Q3 		$1.59M Sell
31,452
-1,149
-4% -$51.6K ﹤0.01% 1835
2020
Q2 		$1.55M Buy
32,601
+9,955
+44% +$463K ﹤0.01% 1789
2020
Q1 		$1.11M Buy
22,646
+8,803
+64% +$448K ﹤0.01% 1787
2019
Q4 		$798K Buy
+13,843
New +$685K ﹤0.01% 2218
2019
Q1 		– Sell
-15,442
Closed -$213K – 3068
2018
Q4 		$213K Buy
+15,442
New +$195K ﹤0.01% 2585

Russell Investments Group's EIDX Position: Q1 2021 in Review

Russell Investments Group sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 29,544 shares — an estimated $3.88M sold.

Russell Investments Group first reported a position in EIDX in Q4 2018 and held it in 6 quarters. The position peaked at $3.88M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

  • Russell Investments Group reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Russell Investments Group sold 29,544 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $3.88M.
  • Russell Investments Group first reported a position in Eidos Therapeutics, Inc. Common Stock in Q4 2018 and held it in 6 quarters.
  • Russell Investments Group's Eidos Therapeutics, Inc. Common Stock position peaked at $3.88M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Russell Investments Group's 13F filing for Q1 2021, filed 10 May 2021.